Amit Rakhit, Md: Ovid Therapeutics' Approach

Amit Rakhit, MD: Ovid Therapeutics' Approach

How Ovid Therapeutics Works With Patient Groups

Amit Rakhit, MD, MBA: Developing Therapies for Fragile X Syndrome

Amit Rakhit, MD, MBA: Measuring Improvement in Fragile X Syndrome, Other Rare Conditions

2019 FAST Summit on Angelman Syndrome - OV101 for the Treatment of AS, Dr. Amit Rhakit, Ovid

FAST

Ovid Therapeutics – OV101 Clinical Trial

FAST

Ovid Therapeutics Update | 2021 KAND Conference | KIF1A.ORG

KIF1A Foundation

Inside a Dopamine-Restoring Cell Therapy for PD with BlueRock Therapeutics' Dr. Amit Rakhit

Life Science Connect

AAV-mediated gene therapy approach: Ovid Therapeutics

FAST

In the clinic: Ovid Therapeutics-OV101 and the engagement with the Angelman community

FAST

Ovid Therapeutics' Focus

Jeremy Levin Discusses Ovid Therapeutics

Ovid Therapeutics: Focusing on Rare Neurologic Diseases

Covid related discussion by Dr. Amit Rakhit from US and Swami Kripanandaji Maharaj from RKM India

Angelman Syndrome Clinical Trial update - OV101

FAST

Amit Singal, MD: Systemic Therapy in a uHCC Patient

Targeted Oncology

2018 FAST Science Summit - OV101 Development Update: STAS Results and What's Next

FAST

BIO tackles Opioid Crisis: Rob Wright with Ovid’s Dr. Jeremy Levin

Biotechnology Innovation Organization

Therapeutic Approach for Recurrent Metastatic Melanoma

Targeted Oncology

Immunotherapy and targeted therapies 3: Your treatment plan

Irish Cancer Society